Pledpharma announces positive results from the Aladote® proof of principle study
24 sept. 2018 02h30 HE
|
PledPharma AB
Stockholm, September 24, 2018. Today PledPharma (publ) announces that the Aladote® proof of principle study in patients with paracetamol overdose at risk of liver damage has successfully met the...
Aladote® uppvisar god säkerhetsprofil i den första kliniska studien – PledPharma planerar ansöka om särläkemedelsstatus i USA
25 juin 2018 02h30 HE
|
PledPharma AB
PledPharma AB (publ) meddelar idag resultaten från en oberoende utvärdering av data från den kliniska proof-of-principle-studien (fas 1b/2a) av Aladote®. Utvärderingen, som utförts av studiens Data...
Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US
25 juin 2018 02h30 HE
|
PledPharma AB
Today PledPharma (publ) announces that the company has received a positive conclusion of the safety evaluation from the Data Safety Monitoring Board for the Aladote proof of principle study in...